2 Reasons Why Eli Lilly's Mounjaro Might Beat Novo Nordisk's Ozempic, and 2 Reasons Why It Might Not
Much like Novo Nordisk's (NYSE: NVO) money-generating medicine Ozempic, Eli Lilly's (NYSE: LLY) drug Mounjaro is intended to treat type 2 diabetes, and it's also prescribed off-label to treat weight loss. Both companies are raking in billions from sales, and both anticipate making even more in the near future.
But their therapies aren't exactly the same, which means that one might end up stealing market share from the other, or at least driving proportionally more growth for the manufacturer.
To figure out how this face-off will play out for shareholders, we'll first examine two reasons why Mounjaro could outcompete Ozempic. Then, we'll check out the counterarguments.
Source Fool.com
